using ibrutinib in chronic lymphocytic leukemia (cll)
Published 8 years ago • 4.2K plays • Length 7:13Download video MP4
Download video MP3
Similar videos
-
11:28
adverse events of ibrutinib in chronic lymphocytic leukemia
-
5:55
pharmacovigilance with ibrutinib in chronic lymphocytic leukemia
-
1:09
dr. byrd on long-term safety data with ibrutinib in cll
-
7:17
the use of ibrutinib in cll
-
1:05
dr. smith on using venetoclax versus ibrutinib in cll
-
1:16
dr. woyach on ibrutinib and peripheral lymphocytosis in patients with chronic lymphocytic leukemia
-
1:03
dr. woyach on the safety of acalabrutinib versus ibrutinib in cll
-
2:15
dr. kay discusses the role of ibrutinib in cll
-
6:32
ibrutinib therapy in chronic lymphocytic leukemia
-
1:00
dr. smith on ibrutinib-based therapies in cll
-
4:07
management of cll progression after ibrutinib
-
1:41
dr. jacobs on the use of ibrutinib in high-risk patients with cll
-
8:26
small-molecule inhibitors: ibrutinib in chronic lymphocytic leukemia
-
2:04
dr. chavez on ongoing efficacy and challenges with ibrutinib in cll
-
0:39
dr. byrd on ibrutinib in cll
-
1:16
dr. jones on long-term outcomes with ibrutinib in cll
-
1:43
dr shadman on dose reductions with ibrutinib in real-world cll
-
0:43
using acalabrutinib in cll patients with ibrutinib intolerance
-
10:21
mechanisms of ibrutinib resistance in chronic lymphocytic leukemia